Diligence memo · auto-generated · as of July 2, 2026
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Lipella Pharmaceuticals Inc. operates in Pharmaceuticals, based in PITTSBURGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lipella Pharmaceuticals Inc. has raised $8.2M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.1M on 2020-10-23.
Most recent recorded round closed around 2024-12-23.
Valuation (modeled)modeled
Provath models Lipella Pharmaceuticals Inc. at approximately $9.6M (range $2.0M–$23M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 22 months.
Last raise 18 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 21.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 50% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.